MyoKardia Inc. (NASDAQ:MYOK)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $20.72 and last traded at $20.44, with a volume of 41,489 shares trading hands. The stock had previously closed at $19.66.

A number of brokerages recently issued reports on MYOK. Zacks Investment Research downgraded MyoKardia from a “hold” rating to a “sell” rating in a report on Friday, August 12th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of MyoKardia in a report on Tuesday, August 9th. BMO Capital Markets began coverage on MyoKardia in a report on Wednesday, July 20th. They issued an “outperform” rating and a $28.00 price target for the company. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $20.00 price target (up from $16.00) on shares of MyoKardia in a report on Tuesday, July 12th. Finally, Cowen and Company reissued a “buy” rating on shares of MyoKardia in a report on Friday, May 13th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $23.50.

The firm’s 50 day moving average is $16.76 and its 200-day moving average is $12.28. The stock’s market capitalization is $535.00 million.

MyoKardia (NASDAQ:MYOK) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.04. The firm earned $3.55 million during the quarter, compared to the consensus estimate of $3.55 million. The company’s quarterly revenue was up .0% compared to the same quarter last year. On average, analysts predict that MyoKardia Inc. will post ($1.50) EPS for the current fiscal year.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.